title: Investigation of a liposomal oxaliplatin drug formulation by capillary electrophoresis hyphenated to inductively coupled plasma mass spectrometry (CE-ICP-MS).
abstract: A capillary electrophoresis-inductively coupled plasma mass spectrometry (CE-ICP-MS) method was developed for separation of the free oxaliplatin drug substance from liposome-entrapped oxaliplatin. Simultaneous determination of phosphorous and platinum opened the possibility to simultaneously monitor the liposomes (phospholipids) and platinum-based drug. In order to suppress the interferences, argon gas was used as a collision gas in ICP-MS. A detection limit of 29 ng/mL of platinum and a precision of 2.9% (for 10 μg/mL of oxaliplatin standard) were obtained. Measurement of the total concentration of free and encapsulated oxaliplatin by CE-ICP-MS was compared with total determination by ICP-MS after microwave digestion and showed a good agreement. A liposomal formulation of oxaliplatin based on PEGylated liposomes was used as a model drug formulation. Studies of accelerated drug release induced by sonication and phospholipase A(2) catalyzed hydrolysis were performed. It was demonstrated that the CE-ICP-MS was an efficient in vitro characterization method in the development and quality assurance purposes of lipsome-based formulation of metallodrugs.
authors.affiliation: Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Tam T T N
authors.initials: TT
authors.lastname: Nguyen
authors.forename: Jesper
authors.initials: J
authors.lastname: Østergaard
authors.forename: Stefan
authors.initials: S
authors.lastname: Stürup
authors.forename: Bente
authors.initials: B
authors.lastname: Gammelgaard
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D019075:Electrophoresis, Capillary / Q000379:methods*; D008081:Liposomes / Q000737:chemistry*; D013058:Mass Spectrometry / Q000379:methods*; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000737:chemistry; D000077150:Oxaliplatin; D010758:Phosphorus / Q000032:analysis; D010984:Platinum / Q000032:analysis*; D012680:Sensitivity and Specificity
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D010758:Phosphorus; D010984:Platinum